The Implications of Colorectal Cancer Molecular Biology in Clinical Practice

Surgical Oncology Clinics of North America

Volumn 17, Issue 2, 2008, Pages 341-355

  Kargozaran, Hamed ^a   Kahlenberg, Morton ^b   Khatri, Vijay P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; BEVACIZUMAB; CETUXIMAB; DIHYDROPYRIMIDINE DEHYDROGENASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROTEIN P53; SMAD PROTEIN; THYMIDYLATE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADJUVANT THERAPY; ANGIOGENESIS; CANCER SCREENING; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CLINICAL PRACTICE; COLON POLYPOSIS; COLONOSCOPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; FECES ANALYSIS; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOLECULAR BIOLOGY; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT BLOOD; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTO ONCOGENE; REVIEW; SIGMOIDOSCOPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; CHROMOSOMAL INSTABILITY; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HUMANS; MASS SCREENING; MICROSATELLITE INSTABILITY; MOLECULAR BIOLOGY; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED; TRANSFORMING GROWTH FACTOR BETA;

EID: 41049083340     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2007.12.005     Document Type: Review

References (108)

1. Jemal A., Siege R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 1 (2007) 43-66
2. Kitisin K., and Mishra L. Molecular biology of colorectal cancer: new targets. Semin Oncol 33 Suppl 11 (2006) 14-23
3. Takayama T., Miyanishi K., Hayashi T., et al. Colorectal cancer: genetics of development and metastasis. J Gastroenterol 41 3 (2006) 185-192
4. Peipins L.A., and Sandler R.S. Epidemiology of colorectal adenomas. Epidemiol Rev 16 2 (1994) 273-297
5. Robbins D.H., and Itzkowitz S.H. The molecular and genetic basis of colon cancer. Med Clin North Am 86 6 (2002) 1467-1495
6. Radtke F., Clevers H., and Riccio O. From gut homeostasis to cancer. Curr Mol Med 6 3 (2006) 275-289
7. Nakamura Y. The role of the adenomatous polyposis coli (APC) gene in human cancers. Adv Cancer Res 62 (1993) 65-87
8. Kinzler K.W., and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87 2 (1996) 159-170
9. Powell S.M., Zilz N., Beazer-Barclay Y., et al. APC mutations occur early during colorectal tumorigenesis. Nature 359 6392 (1992) 235-237
10. Polakis P. Wnt signaling and cancer. Genes Dev 14 15 (2000) 1837-1851
11. Bienz M., and Clevers H. Linking colorectal cancer to Wnt signaling. Cell 103 2 (2000) 311-320
12. Sparks A.B., et al. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 58 6 (1998) 1130-1134
13. Yashiro M., Carethers J., Laghi L., et al. Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Res 61 6 (2001) 2676-2683
14. Arber N., Shapira I., Ratan J., et al. Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology 118 6 (2000) 1045-1050
15. Smakman N., Borel-Rinkes I., Voest E., et al. Control of colorectal metastasis formation by K-Ras. Biochim Biophys Acta 1756 2 (2005) 103-114
16. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 5 (1990) 759-767
17. Hahn S.A., Schutte M., Hoque A., et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271 5247 (1996) 350-353
18. Eppert K., Scherer S., Ozcelik H., et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86 4 (1996) 543-552
19. Somasundaram K. Tumor suppressor p53: regulation and function. Front Biosci 5 (2000) D424-D437
20. Vogelstein B., Fearon E., Hamilton S., et al. Genetic alterations during colorectal-tumor development. N Engl J Med 319 9 (1988) 525-532
21. Thibodeau S.N., Bren G., and Schaid D. Microsatellite instability in cancer of the proximal colon. Science 260 5109 (1993) 816-819
22. Ionov Y., Peinado M., Malkhosyan S., et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363 6429 (1993) 558-561
23. Soreide K., Janssen E., Soiland H., et al. Microsatellite instability in colorectal cancer. Br J Surg 93 4 (2006) 395-406
24. Kim H., Jen J., Vogelstein B., et al. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 145 1 (1994) 148-156
25. Cunningham J.M., Christensen E., Tester D., et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 58 15 (1998) 3455-3460
26. Lind G.E., Thorstensen L., Lovig T., et al. A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol Cancer 3 (2004) 28-39
27. Grady W.M., Myeroff L., Swinler S., et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 59 2 (1999) 320-324
28. Ando T., Sugai T., Habano W., et al. Analysis of SMAD4/DPC4 gene alterations in multiploid colorectal carcinomas. J Gastroenterol 40 7 (2005) 708-715
29. Labbe E., Letamendia A., and Attisano L. Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-beta and wnt pathways. Proc Natl Acad Sci U S A 97 15 (2000) 8358-8363
30. Mayer A., Takimoto M., Fritz E., et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71 8 (1993) 2454-2460
31. Takahashi Y., Kitadai Y., Bucana C., et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55 18 (1995) 3964-3968
32. Takahashi Y., Bucan C., Liu W., et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 88 16 (1996) 1146-1151
33. Wagner H.E., Toth C., Steele G., et al. Metastatic potential of human colon cancer cell lines: relationship to cellular differentiation and carcinoembryonic antigen production. Clin Exp Metastasis 10 1 (1992) 25-31
34. Sun X.F., and Zhang H. Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas. Mol Cancer 5 (2006) 43-63
35. Bird N.C., Mangnall D., and Majeed A.W. Biology of colorectal liver metastases: a review. J Surg Oncol 94 1 (2006) 68-80
36. Grady W.M., and Markowitz S.D. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 3 (2002) 101-128
37. Macdonald J.S. Adjuvant therapy of colon cancer. CA Cancer J Clin 49 4 (1999) 202-219
38. Hardcastle J.D., Chamberlain J., Robinson M., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348 9040 (1996) 1472-1477
39. Loktionov A., O'Neill I., Silvester K., et al. Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer. Clin Cancer Res 4 2 (1998) 337-342
40. Ahlquist D.A. Molecular stool screening for colorectal cancer. Using DNA markers may be beneficial, but large scale evaluation is needed. BMJ 321 7256 (2000) 254-255
41. Yamashita N., Minamoto T., Ochiai A., et al. Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology 108 2 (1995) 434-440
42. Ahlquist D.A., Skoletsky J., Boynton K., et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119 5 (2000) 1219-1227
43. Conlin A., Smith G., Carey F., et al. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 54 9 (2005) 1283-1286
44. Bertario L., Russo A., Sala P., et al. APC genotype is not a prognostic factor in familial adenomatous polyposis patients with colorectal cancer. Dis Colon Rectum 47 10 (2004) 1662-1669
45. Pajkos G., Kiss I., Sandor J., et al. The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. Anticancer Res 20 3A (2000) 1695-1701
46. Andreyev H.J., Norman A., Cunningham D., et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 90 9 (1998) 675-684
47. Ahnen D.J., Feigl P., Quan G., et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 58 6 (1998) 1149-1158
48. Benhattar J., Losi L., Chaubert P., et al. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 104 4 (1993) 1044-1048
49. Morrin M., Kelly M., Barrett N., et al. Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance. Gut 35 11 (1994) 1627-1631
50. Bouzourene H., Gervaz P., Cerottini J., et al. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 36 8 (2000) 1008-1015
51. Bleeker W.A., Hayes V., Karrenbeld A., et al. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer. Am J Gastroenterol 95 10 (2000) 2953-2957
52. Jernvall P., et al. Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J Cancer 79 5-6 (1999) 903-908
53. Font A., Makinen M., Karttunen T., et al. Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum 44 4 (2001) 549-557
54. Shibata D., et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 335 23 (1996) 1727-1732
55. Popat S., and Houlston R.S. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 41 14 (2005) 2060-2070
56. Ookawa K., Sakamoto M., Hirohashi S., et al. Concordant p53 and DCC alterations and allelic losses on chromosomes 13q and 14q associated with liver metastases of colorectal carcinoma. Int J Cancer 53 3 (1993) 382-387
57. Kato M., Sakamoto M., Hirohashi S., et al. Detection of DCC and Ki-ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence. Cancer 77 Suppl 8 (1996) 1729-1735
58. Watanabe T., Wu T., Catalano P., et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344 16 (2001) 1196-1206
59. Dix B.R., Robbins P., Soong R., et al. The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 59 6 (1994) 747-751
60. Carethers J.M., Hawn M., Greenson J., et al. Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 114 6 (1998) 1188-1195
61. Greenblatt M.S., Bennett W., Hollstein M., et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54 18 (1994) 4855-4878
62. Kahlenberg M.S., Sullivan J., Witmer D., et al. Molecular prognostics in colorectal cancer. Surg Oncol 12 3 (2003) 173-186
63. Yamaguchi A., Kurosaka Y., Fushida S., et al. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 70 12 (1992) 2778-2784
64. Buglioni S., D'Agnano I., Cosimelli M., et al. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. Int J Cancer 84 6 (1999) 545-552
65. Soong R., Grieu F., Robbins P., et al. p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 3 8 (1997) 1405-1411
66. Soong R., Powell B., Elsaleh H., et al. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 36 16 (2000) 2053-2060
67. Tang R., Wang J., Fan C., et al. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. Cancer Lett 210 1 (2004) 101-109
68. Bubb V.J., Curtis L., Cunningham C., et al. Microsatellite instability and the role of hMSH2 in sporadic colorectalcancer. Oncogene 12 12 (1996) 2641-2649
69. Sankila R., Aaltonen L., Järvinen H., et al. Better survival rates in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 110 3 (1996) 682-687
70. Salahshor S., Kressner U., Fischer H., et al. Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor. Br J Cancer 81 2 (1999) 190-193
71. Curran B., Lenehan K., Mulcahy H., et al. Replication error phenotype, clinicopathological variables, and patient outcome in Dukes' B stage II (T3,N0,M0) colorectal cancer. Gut 46 2 (2000) 200-204
72. Allegra C.J., Kim G., and Kirsch I.R. Microsatellite instability in colon cancer. N Engl J Med 349 18 (2003) 1774-1776 [author reply 1774-6]
73. Elsaleh H., Joseph D., Grieu F., et al. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355 9217 (2000) 1745-1750
74. Tokunaga T., Oshika Y., Abe Y., et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 77 6 (1998) 998-1002
75. Takahashi Y., Tucker S., Kitadai Y., et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 132 5 (1997) 541-546
76. Karayiannakis A.J., Syrigos K., Zbar A., et al. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery 131 5 (2002) 548-555
77. Amaya H., Tanigawa N., Lu C., et al. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett 119 2 (1997) 227-235
78. Anwar S., Frayling I., Scott N., et al. Systematic review of genetic influences on the prognosis of colorectal cancer. Br J Surg 91 10 (2004) 1275-1291
79. Mamounas E., Wieand S., Wolmark N., et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17 5 (1999) 1349-1355
80. Gill S., Loprinzi C., Sargent D., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol 22 10 (2004) 1797-1806
81. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 23 (2004) 2343-2351
82. Monga D.K., and O'Connell M.J. Surgical adjuvant therapy for colorectal cancer: current approaches and future directions. Ann Surg Oncol 13 8 (2006) 1021-1034
83. Johnston P.G., Drake J., Trepel J., et al. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52 16 (1992) 4306-4312
84. Leichman C.G., Lenz H., Leichman L., et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15 10 (1997) 3223-3229
85. Shirota Y., Stoehlmacher J., Brabender J., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19 23 (2001) 4298-4304
86. Stoehlmacher J., and Lenz H.J. Implications of genetic testing in the management of colorectal cancer. Am J Pharmacogenomics 3 2 (2003) 73-88
87. Metzger R., Danenberg K., Leichman C., et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 4 10 (1998) 2371-2376
88. Ishikawa T., Sekiguchi F., Fukase Y., et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58 4 (1998) 685-690
89. Iqbal S., and Lenz H.J. Targeted therapy and pharmacogenomic programs. Cancer 97 Suppl 8 (2003) 2076-2082
90. Salonga D., Danenberg K., Johnson M., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6 4 (2000) 1322-1327
91. Lu Z., Zhang R., and Diasio R.B. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53 22 (1993) 5433-5438
92. Zhang W., Gordon M., and Lenz H.J. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann Med 38 8 (2006) 545-551
93. Arteaga C.L. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19 Suppl 18 (2001) 32S-40S
94. Saltz L.B., Meropol N., Loehrer P., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 7 (2004) 1201-1208
95. Lenz H.J. First Amsterdam, then Bethesda, now Melbourne?. J Clin Oncol 23 27 (2005) 6445-6449
96. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 4 (2004) 337-345
97. Yang X.D., Jia X., Corvalan J., et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38 1 (2001) 17-23
98. Berlin J., Posey J., Tchekmedyian S., et al. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 6 6 (2007) 427-432
99. Chung K.Y., and Saltz L.B. Antibody-based therapies for colorectal cancer. Oncologist 10 9 (2005) 701-709
100. Kabbinavar F., Hurwitz H., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 1 (2003) 60-65
101. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
102. Jager P.L., de Korte M., Lub-de Hooge M., et al. Molecular imaging: what can be used today. Cancer Imaging 5 Spec No A (2005) S27-S32
103. Pomper M.G. Molecular imaging: an overview. Acad Radiol 8 11 (2001) 1141-1153
104. McLarty K., and Reilly R.M. Molecular imaging as a tool for personalized and targeted anticancer therapy. Clin Pharmacol Ther 81 3 (2007) 420-424
105. Iyer R. Imaging colorectal cancer. Semin Roentgenol 41 2 (2006) 113-120
106. Schwaiger M., and Peschel C. Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy. Eur J Nucl Med Mol Imaging 33 Suppl 1 (2006) 1-5
107. Harte R.J., Matthews J., O'Reilly S., et al. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. J Clin Oncol 17 5 (1999) 1580-1588
108. Rehman S., and Jayson G.C. Molecular imaging of antiangiogenic agents. Oncologist 10 2 (2005) 92-103